6th Time's A Charm For Gilead Securities Action

Law360, New York (October 14, 2009, 4:38 PM EDT) -- A federal judge has ruled that plaintiffs in a putative securities class action against Gilead Sciences Inc. have sufficiently buttressed their claims that the company boosted profits through off-label sales of its drugs, denying a motion to dismiss a fifth amended complaint in the case.

In a ruling Tuesday in the U.S. District Court for the Northern District of California, Judge Susan Illston said that statements from six confidential witnesses added to the plaintiffs' fifth amended complaint overcame inconsistencies from a version that was dismissed in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.